ดาวน์โหลดงานนำเสนอ
งานนำเสนอกำลังจะดาวน์โหลด โปรดรอ
1
Laboratory interpretation
Lalita Norasetthada, MD Hematology Division, Department of internal medicine, CMU
2
Laboratory interpretation
Hematology lab CBC Coagulogram Blood chemistry Liver function Kidney function FPG and lipid profile Serologic test
3
Normal Laboratory Values
Abnormal 2 SD mild elevation in 2.5% of normal population normal range included a small subset of patients with subclinical liver disease normal values = mean ± 2SD of normal population
4
CBC : Complete Blood Count
5
CBC
6
White blood cell count ปริมาณลดลง ปริมาณเพิ่มขึ้น การติดเชื้อไวรัส
Normal range 4,500-10,000 cell/mm3 x 103/uL ปริมาณลดลง การติดเชื้อไวรัส ยาบางชนิด โรคของไขกระดูกทำให้สร้างเม็ดเลือดขาวลดลง ปริมาณเพิ่มขึ้น การตอบสนองของร่างกายปกติที่เกิดในภาวะติดเชื้อหรือการ อักเสบ (< 30,000/uL) มะเร็งเม็ดเลือดขาว
9
WBC morphology
10
Increased risk of infection when Absolute neutrophil count (ANC)
< 1,000/mm3 or 1.0 x 103/uL
11
CBC
12
Hemoglobin Hematocrit การตรวจ ค่าผลการตรวจ ภาวะเสียเลือด
ต่ำ สูง Hemoglobin Hematocrit ภาวะเสียเลือด ขาดสารอาหาร เช่น ธาตุเหล็ก, ขาดวิตามิน ภาวะเม็ดเลือดแดงแตก จากการติดเชื้อ, สารพิษ, ยา หรือดแตกเองในร่างกาย ไขกระดูกผ่อหรือไม่ทำงาน มะเร็งของเม็ดเลือด ขาดสารน้ำ ภาวะที่มี OXYGEN ในเลือดต่ำเรื้อรัง เช่น สูบบุหรี่ ไขกระดูกสร้างเม็ดเลือดสูงผิดปกติ
13
RBC morphology
14
Concerning values For general dental procedure Procedure under GA
Hb > 7 gm/dl Procedure under GA Hb > gm/dl
15
CBC
16
การนับจำนวนเกร็ดเลือด (platelet count)
100, ,000/mm3 x 103/uL
17
เกร็ดเลือด การตรวจ ค่าผลการตรวจ ม้ามโต
ต่ำ สูง เกร็ดเลือด ม้ามโต เกร็ดเลือดถูกทำลายมากขึ้น จากยา, ภูมิต้านทาน เกร็ดเลือดสร้างได้น้อยจากความผิดปกติของไขกระดูก ไขกระดูกฝ่อ หรือทำงานผิดปกติ ไขกระดูกถูกแทรกซึมจากการติดเชื้อหรือมะเร็ง โรคมะเร็งเม็ดเลือด การอักเสบหรือการติดเชื้อเรื้อรัง มะเร็งของอวัยวะอื่น โรคไขกระดูกสร้างเม็ดเลือดเพิ่มมากผิดปกติ มะเร็งเม็ดเลือดขาวเรื้อรัง
18
Platelet morphology
19
Increased risk of bleeding when
Platelet count <50,000/mm3 or < 50 x 103/uL > 1,000,000/mm3 or > 1,000 x 103/uL In mild thrombocytopenia, all dental procedure can be done safely (50, ,000/mm3)
20
Coagulation test
21
Primary hemostasis
22
Secondary Hemostasis In vivo In vitro
23
Coagulation test PT : prothrombin time
Range 8-11 seccods aPTT : activated partial thromblastin time Range seconds
24
Isolated PT Prolongation
Inherited FVII deficiency Acquired Vitamin K deficiency Liver disease Warfarin administration Inhibitor of FVII
25
Isolated PTT prolongation
Inherited Deficiency of F VIII, IX, XI Deficiency of FXII, prekallikrein, HMW kininogen VWD Acquired Lupus anticoagulant Inhibitor to FVIII, IX, XI, XII Heparin administration
26
Combined PT and PTT prolongation
Inherited Deficiency of FV, X, fibrinogen, prothrombin Acquired Liver disease DIC Supratherapeutic dose of warfarin and heparin Inhibitor of FV, X, fibrinogen, prothrombin Primary amyloidosis associated FX deficiency
27
Bleeding risk Increased risk of bleeding after invasive procedure when
Either PT or aPTT increases > 1.5 folds above mid normal range Ex. PT 24 secs (8-12), INR 2.5 PTT 40 secs (28-32)
28
Bleeding disorder in the setting of normal screening test
Platelet dysfunction Drug : aspirin, NSAID, clopidrogrel Chronic disease : liver/kidney failure Hereditary disorder Impaired fibrin crosslink and fibrinolytic disorder
29
Blood Chemistry BUN Cr Kidney function Albumin / Globulin GOT / GPT
Alk. Phosphatase Cholesterol Bilirubin Triglyceride HDL LDL Plasma glucose Kidney function Liver function test Lipid Profile
30
Kidney function test
31
Laboratory test to evaluate kidney function
Glomerular filtration rate (GFR) Plasma creatinine Plasma urea Urine volume Urine electrolytes, protein, urea, osmolality
32
Glomerular filtration rate
Value always adapted to the BSA!! Ideal BSA in adults is 1.73m2 Schwartz equation : GFR= v x 0.808 Pcr (umol/L) How to assess easy if plasma creatinine is OK
33
Creatinine and Urea Plasma Concentration- hyperbolic correlation
pCr, pUrea Lower limit 90 ml/Min./1.73 m2 Normal range-> 140 mL/min (100%) 0 mL/min (0%) GFR 50%
34
Plasma urea (BUN) BUN (blood urea nitrogen) 10-20 mg/dl
Urea: product of protein catabolism Synthesized by liver, excreted by kidney, partially reabsorbed in tubuli Plasma concentration increases with decreased GFR
35
BUN in patients with kidney diseases
Useful test but must be interpreted with great care urea plasma level is more than creatinine dependent on protein intake Most useful when considered along with creatinine High in high protein intake, UGI bleeding Low in severe liver dysfunction
36
Plasma creatinine and renal function
Creatine : main storage compound of high energy phosphate needed for muscle metabolism Creatinine: anhydride of creatine Creatinine is freely filtered by the glomerulii and is not reabsorbed In most circumstances the measurement of plasma creatinine can provide a specific test of glomerular function. The reference range is wide. A body builder may have a plasma creatinine at the top end and an old lady a value at the low end and this reflects muscle mass. Plasma creatinine should not be measured until 8 hours after a meal as there is some evidence that the concentration increases after meat ingestion. Plasma creatinine concentration increases when GFR falls. The problem is that GFR has to fall quite a bit before plasma creatinine concentration reliably increases. There are some important analytical interferences which you should check with the laboratory. A patient with ketoacidosis, jaundice or infection might have agents in the plasma which could invalidate the measurement of creatinine. Overhead 1 follows Creatine Creatinine (Waste product) H2O
37
Analytic method Plasma creatinine Male 0.6-1.2 mg/dL,
Female mg/dL Pre-renal disorder BUN:Cr ratio >20 Renal and postrenal disorders BUN: Cr both elevated
38
Liver function test
39
Liver Function Test Liver chemistry test
Clinical implication of abnormality ALT Hepatocellular damage AST Bilirubin Cholestasis, impair conjugation, or biliary obstruction ALP Cholestasis, infiltrative disease, or biliary obstruction PT Synthetic function Albumin GGT Cholestasis or biliary obstruction Bile acids 5`-nucleotidase LDH Hepatocellular damage, not specific no single test provide accurate global assessment of hepatic function
40
Normal values
41
Liver Function Test Advantages
Sensitive, noninvasive method of screening liver dysfunction Pattern of laboratory test abnormalities to recognize type of liver disorder Assess severity of liver dysfunction Follow cause of liver disease Disadvantages Not specific for liver dysfunction Seldom lead to specific diagnosis
42
Liver function test
43
Liver Function Test Classified in 3 groups
Synthetic function : albumin, prothrombin time (PT) Hepatocyte injury : AST, ALT Cholestasis : bilirubin, ALP, GGT PT, albumin, bilirubin : most common tests used as prognostic factors
44
Liver function test
45
Albumin Depending on nutrition, volume status, vascular integrity, catabolism, hormone, loss in stool and urine Not specific for liver disease T1/ D decrease : poor nutrition status, severe illness with protein catabolism, nephrosis, malabsorption, PLE, burns, heavy alcohol intake
46
Globulin Produced by stimulated B-lymphocyte Elevation in
chronic liver disease chronic inflammation and malignant disease
47
Hypoalbuminemia globulin chol/TG Hb 1.decrease synthesis
-protein malnutrition -chronic liver disease -chronic inflammation 2.increase loss -Protein loosing enteropathy -NS 3.increase Vd (ascites, overhydration)
48
Metabolic Syndrome
49
Cardiometabolic Risk - Graphic
Overweight / Obesity Glucose BP Lipids Age Genetics Insulin Resistance Abnormal Lipid Metabolism LDL ApoB HDL Trigly. Insulin Resistance Syndrome Cardiometabolic Risk Global Diabetes / CVD Risk Age, Race, Gender, Family History Start off with a rundown of cardiometabolic risk factors Smoking Physical Inactivity Unhealthy Eating Inflammation Hypercoagulation Hypertension
50
Interpreting Blood Glucose Levels
Fasting glucose : No caloric intake > 8 hours Healthy BG FPG < 100 mg/dL Pre-diabetes FPG 100–125 mg/dL (Impaired fasting glucose) Diabetes FPG ≥126 mg/dL Random plasma glucose PG > 200 mg/dl
51
Total Cholesterol Goals34
Desirable — Less than 200 mg/dL Borderline high risk — 200–239 mg/dL High risk — 240 mg/dL and over American Diabetes Association. Understanding Cardiometabolic Risk: Broadening Risk Assessment and Management, Dyslipidemia Richard M Bergenstal, MD International Diabetes Center
52
Lipid profile No caloric intake > 12 H Lipid profle
Total choleterol LDL HDL TG
53
Cholesterol Management
LDL-C-lowering Category of risk LDL-C Goal 0-1 risk factor* < 160 mg/dL or lower Multiple (2+) risk factors* < 130 mg/dL or lower People with coronary heart disease or risk equivalent (e.g., diabetes) < 100 mg/dL or lower Known CAD and DM < 70 mg/dL or lower may be ideal
54
Serologic tests
55
Test and window period Virus marker window period mean range
HBV HBsAg HCV anti-HCV HIV anti-HIV-1/ HTLV anti-HTLV-I NAT yield in Thailand : The National Blood Centre Thai Red Cross Society HIV 1:97,000 HCV 1:490,000, HBV 1:2,800
56
Viral hepatits Acute AntiHAV HBsAg Chronic AntiHCV
57
Main Ways to Get Hepatitis A
1 Fecal-oral route
58
Viral hepatitis A
59
Main Ways to Get Hepatitis B
1 Having sex without condoms with someone who has hepatitis B 2 Being born to a mother who has hepatitis B 3 Sharing needles and syringes Receiving blood component from HBV infected donor 4
60
Natural history of HBV - related infection
Acute hepatitis Asymptomatic 30% Fulminant hepatitis 1% Contamination 95% 5% Resolution Chronic infection 66% 33% Chronic hepatitis 10-20% Inactive carriage HCC Cirrhosis 3-5% yearly
61
Viral hepatitis B
62
Hepatitis B can be prevented!
If you have never had hepatitis B, you can get 3 shots . . . 3 2 1 . . . and get long lasting protection.
63
Main Ways to Get Hepatitis C
1 Sharing needles and syringes 2 Receiving blood component from HCV infected donor
64
Hepatitis C Virus (HCV)
HCV Infection Acute infection Mild symptoms 50-70% of affected patients develop chronic hepatitis 20% of affected patients develop cirrhosis or hepatocellular carcinoma
65
Viral hepatitis C
66
HIV infection AIDs situation in Thailand, March 2011 Prevalence 0.6%
Total HIV infected cases 372,874 persons Already died 98,153 persons
67
Main Ways to HIV 1 2 3 4 Being born to a mother who has HIV
Having sex without condoms with HIV infected persons 2 Being born to a mother who has HIV 3 Sharing needles and syringes Receiving blood component from HBV infected donor 4
68
HIV Strauss JM & Strauss EG,2002
69
Who to Test for HIV High risk groups include MSM
Injection drug users or history injection drugs Heterosexual partners of those listed above Those interested in HIV testing People presenting with an opportunistic infection or recurrent/severe infections that can not otherwise be explained Adults with thrush, recurrent pneumonia
70
HIV Testing EIA- standard serologic screening test
Needs to be repeatedly positive Should not give the patient this test result until confirmed Western Blot-confirmatory test. 2 bands of the following: p24, gp41 or gp120/160 Antibodies to p24 and p55 appear earliest but decrease or become undetectable. Antibodies to gp31, gp41, gp120, and gp160 appear later but are present throughout all stages of the disease EIA and Western Blot >99.9% sensitive and specific
71
Window period in HIV infection
72
HIV Testing 4-20% of test results are indeterminate with WB assays with positive bands for HIV-1 proteins Causes of indeterminate tests include Patients in the process of seroconversion HIV-2 infection Cross-reacting nonspecific antibodies Testing should be repeated at 6-8 weeks, 3, and 6 months The reason for cross reacting with nonspecific antibodies include idu, cvd, autoimmune disease, lymphoma liver disease, ms and pregnancy May lose the core ab in late stage disease New tests now available SUDS, orasure and to be available soon
73
HIV Testing Rapid testing Two tests FDA approved, SUDS and Oraquick
Oraquick much easier and very accurate Sensitivity and Specificity is 99.5% Positives still need confirmation Similar to performing a pregnancy test
74
The End
งานนำเสนอที่คล้ายกัน
© 2024 SlidePlayer.in.th Inc.
All rights reserved.